Past use of oral contraceptives and the risk of developing systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 40, Issue 5, 1997, Pages 804-808

  Sanchez Guerrero, Jorge ^a,b   Karlson, Elizabeth W ^b   Liang, Matthew H ^b   Hunter, David J ^c   Speizer, Frank E ^c   Colditz, Graham A ^c,d  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d CHANNING LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT; SEX HORMONE;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GLOMERULONEPHRITIS; HUMAN; IMMUNE COMPLEX DEPOSITION; INCIDENCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; SEX DIFFERENCE; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0030967338     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780400505     Document Type: Article

References (26)

1. Alarcón-Segovia D: The pathogenesis of immune dysregulation in systemic lupus erythematosus: a troika. J Rheumatol 11:588-590, 1984
2. Masi AT, Kaslow RA: Sex effects in systemic lupus erythematosus: a clue to pathogenesis. Arthritis Rheum 21:480-484, 1978
3. Sanchez-Guerrero J, Liang MH, Karlson EW, Hunter DJ, Colditz GA: Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med 122:430-433, 1995
4. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271-1277, 1982
5. Karlson EW, Sanchez-Guerrero J, Wright EA, Lew RA, Daltroy LH, Katz JN, Liang MH: A connective tissue disease screening questionnaire (CSQ) for population studies. Ann Epidemiol 5:297-302, 1995
6. Lom-Orta H, Alarcón-Segovia D, Diaz-Jouanen E: Systemic lupus erythematosus: differences between patients who do, and who do not, fulfill classification criteria at the time of diagnosis. J Rheumatol 7:831-837, 1980
7. Rothman KJ, Boice JD: Epidemiologic Analysis with a Programmable Calculator (NIH publication no. 79-1649). Washington DC, Public Health Service, 1979
8. Strom BL, Reidenberg MM, West S, Snyder ES, Freundlich B, Stolley PD: Shingles, allergies, family medical history, oral contraceptives, and other potential risk factors for systemic lupus erythematosus. Am J Epidemiol 140:632-642, 1994
9. Hochberg MC, Kaslow RA: Risk factors for the development of systemic lupus erythematosus: a case-control study (abstract). Clin Res 31:732A, 1983
10. Spiera H, Plotz CM: Rheumatic symptoms and oral contraceptives (letter). Lancet i:571, 1969
11. Garovich M, Agudelo C, Pisko E: Oral contraceptives and systemic lupus erythematosus. Arthritis Rheum 23:1396-1398, 1980
12. Chapel TA, Burns RE: Oral contraceptives and exacerbation of lupus erythematosus. Am J Obstet Gynecol 110:366-369, 1971
13. Schleicher EM: LE cells after oral contraceptives. Lancet i:821-822, 1968
14. Lahita RG, Bradlow HL, Kunkel HG, Fishman J: Increased 16-α hydroxylation of estradiol in systemic lupus erythematosus. J Clin Endocrinol Metab 53:174-178, 1981
15. Jungers P, Nahoul K, Pelissier C, Dougados M, Tron F, Bach J-F: Low plasma androgens in women with active or quiescent systemic lupus erythematosus. Arthritis Rheum 25:454-457, 1982
16. Lahita RG, Bradlow HL, Ginzler E, Pang S, New M: Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum 30:241-248, 1987
17. Dubois EL, Strain L, Mita E, Bernstein G, Friou GJ: LE cells after oral contraceptives (letter). Lancet ii:679, 1968
18. Kelley VE, Winkelstein A: Age- and sex-related glomerulonephritis in New Zealand white mice. Clin Immunol Immunopathol 16:142-150, 1980
19. Roubinian JR, Talal N, Greenspan JS, Goodman JR, Siiteri PK: Delayed androgen treatment prolongs survival in murine lupus. J Clin Invest 63:902-911, 1979
20. Roubinian JR, Talal N, Greenspan JS, Goodman JR, Siiteri PK: Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. J Exp Med 147:1568-1583, 1978
21. Colditz GA, Martin P, Stampfer MJ, Willett WC, Sampson L, Rosner B, Hennekens CH, Speizer FE: Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol 123:894-900, 1986
22. Michet CJ Jr, McKenna CH, Elveback LR, Kaslow RA, Kurland LT: Epidemiology of SLE and other connective tissue diseases in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 60: 105-113, 1985
23. Hochberg MC: The incidence of systemic lupus erythematosus in Baltimore, Maryland, 1970-1977. Arthritis Rheum 28:80-86, 1985
24. Nived O, Sturfelt G, Wollheim F: Systemic lupus erythematosus in an adult population in southern Sweden: incidence, prevalence and validity of ARA revised classification criteria. Br J Rheumatol 24:147-154, 1985
25. Siegel M, Lee SL: The epidemiology of systemic lupus erythematosus. Semin Arthritis Rheum 3:1-54, 1973
26. Baird DT, Glasier AF: Hormonal contraception. N Engl J Med 328:1543-1549, 1993